Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1997 Sep 1;100(5):1114–1122. doi: 10.1172/JCI119622

Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes.

K W Wucherpfennig 1, I Catz 1, S Hausmann 1, J L Strominger 1, L Steinman 1, K G Warren 1
PMCID: PMC508286  PMID: 9276728

Abstract

Myelin basic protein (MBP) may be an important autoantigen in multiple sclerosis (MS), with the MBP(82-100) region being immunodominant for T cells and autoantibodies. The structural requirements for autoantibody recognition were compared to those previously defined for MBP-specific T cell clones. MBP autoantibodies were affinity-purified from central nervous system lesions of 11/12 postmortem cases studied. The MBP(83-97) peptide was immunodominant in all 11 cases since it inhibited autoantibody binding to MBP > 95%. Residues contributing to autoantibody binding were located in a 10-amino acid segment (V86-T95) that also contained the MHC/T cell receptor contact residues of the T cell epitope. In the epitope center, the same residues were important for antibody binding and T cell recognition. Based on the antibody-binding motif, microbial peptides were identified that were bound by purified autoantibodies. Autoantibody binding of microbial peptides required sequence identity at four or five contiguous residues in the epitope center. Microbial peptides previously found to activate T cell clones did not have such obvious homology to MBP since sequence identity was not required at MHC contacts. The similar fine specificity of B cells and T cells may be useful for tolerance induction to MBP in MS.

Full Text

The Full Text of this article is available as a PDF (256.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Brocke S., Gijbels K., Allegretta M., Ferber I., Piercy C., Blankenstein T., Martin R., Utz U., Karin N., Mitchell D. Treatment of experimental encephalomyelitis with a peptide analogue of myelin basic protein. Nature. 1996 Jan 25;379(6563):343–346. doi: 10.1038/379343a0. [DOI] [PubMed] [Google Scholar]
  2. Forghani B., Cremer N. E., Johnson K. P., Ginsberg A. H., Likosky W. H. Viral antibodies in cerebrospinal fluid of multiple sclerosis and control patients: comparison between radioimmunoassay and conventional techniques. J Clin Microbiol. 1978 Jan;7(1):63–69. doi: 10.1128/jcm.7.1.63-69.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Fujinami R. S., Oldstone M. B. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science. 1985 Nov 29;230(4729):1043–1045. doi: 10.1126/science.2414848. [DOI] [PubMed] [Google Scholar]
  4. Gaur A., Wiers B., Liu A., Rothbard J., Fathman C. G. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science. 1992 Nov 27;258(5087):1491–1494. doi: 10.1126/science.1279812. [DOI] [PubMed] [Google Scholar]
  5. Gerritse K., Deen C., Fasbender M., Ravid R., Boersma W., Claassen E. The involvement of specific anti myelin basic protein antibody-forming cells in multiple sclerosis immunopathology. J Neuroimmunol. 1994 Jan;49(1-2):153–159. doi: 10.1016/0165-5728(94)90191-0. [DOI] [PubMed] [Google Scholar]
  6. Jardetzky T. S., Brown J. H., Gorga J. C., Stern L. J., Urban R. G., Strominger J. L., Wiley D. C. Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc Natl Acad Sci U S A. 1996 Jan 23;93(2):734–738. doi: 10.1073/pnas.93.2.734. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Kamholz J., de Ferra F., Puckett C., Lazzarini R. Identification of three forms of human myelin basic protein by cDNA cloning. Proc Natl Acad Sci U S A. 1986 Jul;83(13):4962–4966. doi: 10.1073/pnas.83.13.4962. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Lanzavecchia A. Antigen-specific interaction between T and B cells. Nature. 1985 Apr 11;314(6011):537–539. doi: 10.1038/314537a0. [DOI] [PubMed] [Google Scholar]
  9. Lanzavecchia A. Receptor-mediated antigen uptake and its effect on antigen presentation to class II-restricted T lymphocytes. Annu Rev Immunol. 1990;8:773–793. doi: 10.1146/annurev.iy.08.040190.004013. [DOI] [PubMed] [Google Scholar]
  10. Martin R., Jaraquemada D., Flerlage M., Richert J., Whitaker J., Long E. O., McFarlin D. E., McFarland H. F. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J Immunol. 1990 Jul 15;145(2):540–548. [PubMed] [Google Scholar]
  11. Miick S. M., Martinez G. V., Fiori W. R., Todd A. P., Millhauser G. L. Short alanine-based peptides may form 3(10)-helices and not alpha-helices in aqueous solution. Nature. 1992 Oct 15;359(6396):653–655. doi: 10.1038/359653a0. [DOI] [PubMed] [Google Scholar]
  12. Nonoyama S., Hollenbaugh D., Aruffo A., Ledbetter J. A., Ochs H. D. B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells. J Exp Med. 1993 Sep 1;178(3):1097–1102. doi: 10.1084/jem.178.3.1097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Oldstone M. B. Molecular mimicry and autoimmune disease. Cell. 1987 Sep 11;50(6):819–820. doi: 10.1016/0092-8674(87)90507-1. [DOI] [PubMed] [Google Scholar]
  14. Ota K., Matsui M., Milford E. L., Mackin G. A., Weiner H. L., Hafler D. A. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature. 1990 Jul 12;346(6280):183–187. doi: 10.1038/346183a0. [DOI] [PubMed] [Google Scholar]
  15. Paul W. E., Seder R. A. Lymphocyte responses and cytokines. Cell. 1994 Jan 28;76(2):241–251. doi: 10.1016/0092-8674(94)90332-8. [DOI] [PubMed] [Google Scholar]
  16. Pette M., Fujita K., Wilkinson D., Altmann D. M., Trowsdale J., Giegerich G., Hinkkanen A., Epplen J. T., Kappos L., Wekerle H. Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A. 1990 Oct;87(20):7968–7972. doi: 10.1073/pnas.87.20.7968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Rammensee H. G., Friede T., Stevanoviíc S. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995;41(4):178–228. doi: 10.1007/BF00172063. [DOI] [PubMed] [Google Scholar]
  18. Simitsek P. D., Campbell D. G., Lanzavecchia A., Fairweather N., Watts C. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J Exp Med. 1995 Jun 1;181(6):1957–1963. doi: 10.1084/jem.181.6.1957. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell. 1996 May 3;85(3):299–302. doi: 10.1016/s0092-8674(00)81107-1. [DOI] [PubMed] [Google Scholar]
  20. Stern L. J., Brown J. H., Jardetzky T. S., Gorga J. C., Urban R. G., Strominger J. L., Wiley D. C. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 1994 Mar 17;368(6468):215–221. doi: 10.1038/368215a0. [DOI] [PubMed] [Google Scholar]
  21. Valli A., Sette A., Kappos L., Oseroff C., Sidney J., Miescher G., Hochberger M., Albert E. D., Adorini L. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest. 1993 Feb;91(2):616–628. doi: 10.1172/JCI116242. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Vartdal F., Vandvik B., Norrby E. Viral and bacterial antibody responses in multiple sclerosis. Ann Neurol. 1980 Sep;8(3):248–255. doi: 10.1002/ana.410080305. [DOI] [PubMed] [Google Scholar]
  23. Vogt A. B., Kropshofer H., Kalbacher H., Kalbus M., Rammensee H. G., Coligan J. E., Martin R. Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J Immunol. 1994 Aug 15;153(4):1665–1673. [PubMed] [Google Scholar]
  24. Warren K. G., Catz I. Autoantibodies to myelin basic protein within multiple sclerosis central nervous system tissue. J Neurol Sci. 1993 Apr;115(2):169–176. doi: 10.1016/0022-510x(93)90221-j. [DOI] [PubMed] [Google Scholar]
  25. Warren K. G., Catz I. Diagnostic value of cerebrospinal fluid anti-myelin basic protein in patients with multiple sclerosis. Ann Neurol. 1986 Jul;20(1):20–25. doi: 10.1002/ana.410200105. [DOI] [PubMed] [Google Scholar]
  26. Warren K. G., Catz I. Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis. J Neuroimmunol. 1993 Mar;43(1-2):87–96. doi: 10.1016/0165-5728(93)90078-d. [DOI] [PubMed] [Google Scholar]
  27. Warren K. G., Catz I., Johnson E., Mielke B. Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann Neurol. 1994 Mar;35(3):280–289. doi: 10.1002/ana.410350307. [DOI] [PubMed] [Google Scholar]
  28. Warren K. G., Catz I. Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. J Neurol Sci. 1994 Jan;121(1):66–73. doi: 10.1016/0022-510x(94)90158-9. [DOI] [PubMed] [Google Scholar]
  29. Warren K. G., Catz I., Steinman L. Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features. Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):11061–11065. doi: 10.1073/pnas.92.24.11061. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Warren K. G., Catz I. Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid. J Neuroimmunol. 1992 Jul;39(1-2):81–89. doi: 10.1016/0165-5728(92)90177-m. [DOI] [PubMed] [Google Scholar]
  31. Whitaker J. N., Seyer J. M. The sequential limited degradation of bovine myelin basic protein by bovine brain cathepsin D. J Biol Chem. 1979 Aug 10;254(15):6956–6963. [PubMed] [Google Scholar]
  32. Wucherpfennig K. W., Hafler D. A., Strominger J. L. Structure of human T-cell receptors specific for an immunodominant myelin basic protein peptide: positioning of T-cell receptors on HLA-DR2/peptide complexes. Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8896–8900. doi: 10.1073/pnas.92.19.8896. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Wucherpfennig K. W., Ota K., Endo N., Seidman J. G., Rosenzweig A., Weiner H. L., Hafler D. A. Shared human T cell receptor V beta usage to immunodominant regions of myelin basic protein. Science. 1990 May 25;248(4958):1016–1019. doi: 10.1126/science.1693015. [DOI] [PubMed] [Google Scholar]
  34. Wucherpfennig K. W., Sette A., Southwood S., Oseroff C., Matsui M., Strominger J. L., Hafler D. A. Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J Exp Med. 1994 Jan 1;179(1):279–290. doi: 10.1084/jem.179.1.279. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Wucherpfennig K. W., Strominger J. L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell. 1995 Mar 10;80(5):695–705. doi: 10.1016/0092-8674(95)90348-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Wucherpfennig K. W., Weiner H. L., Hafler D. A. T-cell recognition of myelin basic protein. Immunol Today. 1991 Aug;12(8):277–282. doi: 10.1016/0167-5699(91)90126-E. [DOI] [PubMed] [Google Scholar]
  37. Wucherpfennig K. W., Zhang J., Witek C., Matsui M., Modabber Y., Ota K., Hafler D. A. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol. 1994 Jun 1;152(11):5581–5592. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES